215 related articles for article (PubMed ID: 28646565)
1. Complete molecular remission in relapsed and refractory acute myeloid leukaemia with MLL-AF9 treated with chidamide-based chemotherapy.
Lun Y; Yang JJ; Wu Y
J Clin Pharm Ther; 2017 Dec; 42(6):786-789. PubMed ID: 28646565
[TBL] [Abstract][Full Text] [Related]
2. Co-inhibition of HDAC and MLL-menin interaction targets MLL-rearranged acute myeloid leukemia cells via disruption of DNA damage checkpoint and DNA repair.
Ye J; Zha J; Shi Y; Li Y; Yuan D; Chen Q; Lin F; Fang Z; Yu Y; Dai Y; Xu B
Clin Epigenetics; 2019 Oct; 11(1):137. PubMed ID: 31590682
[TBL] [Abstract][Full Text] [Related]
3. Chidamide, decitabine, cytarabine, aclarubicin, and granulocyte colony-stimulating factor (CDCAG) in patients with relapsed/refractory acute myeloid leukemia: a single-arm, phase 1/2 study.
Wang L; Luo J; Chen G; Fang M; Wei X; Li Y; Liu Z; Zhang Y; Gao S; Shen J; Wang X; Gao X; Zhou W; Ma Y; Liu H; Li X; Yang L; Sun K; Yu L
Clin Epigenetics; 2020 Sep; 12(1):132. PubMed ID: 32873343
[TBL] [Abstract][Full Text] [Related]
4. [Prognostic significance of detecting MLL-AF9 fusion gene expression in patients with acute myeloid leukemia by real-time fluorescence quantitative PCR].
Huang S; Yang H; Gao L; Dou LP; Xu YY; Wang N; Wang LL; Yu L
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Dec; 21(6):1435-40. PubMed ID: 24370025
[TBL] [Abstract][Full Text] [Related]
5. The CDK9 Inhibitor Dinaciclib Exerts Potent Apoptotic and Antitumor Effects in Preclinical Models of MLL-Rearranged Acute Myeloid Leukemia.
Baker A; Gregory GP; Verbrugge I; Kats L; Hilton JJ; Vidacs E; Lee EM; Lock RB; Zuber J; Shortt J; Johnstone RW
Cancer Res; 2016 Mar; 76(5):1158-69. PubMed ID: 26627013
[TBL] [Abstract][Full Text] [Related]
6. Chidamide increases the sensitivity of refractory or relapsed acute myeloid leukemia cells to anthracyclines via regulation of the HDAC3 -AKT-P21-CDK2 signaling pathway.
Wang H; Liu YC; Zhu CY; Yan F; Wang MZ; Chen XS; Wang XK; Pang BX; Li YH; Liu DH; Gao CJ; Liu SJ; Dou LP
J Exp Clin Cancer Res; 2020 Dec; 39(1):278. PubMed ID: 33298132
[TBL] [Abstract][Full Text] [Related]
7. Cooperative effect of chidamide and chemotherapeutic drugs induce apoptosis by DNA damage accumulation and repair defects in acute myeloid leukemia stem and progenitor cells.
Li Y; Wang Y; Zhou Y; Li J; Chen K; Zhang L; Deng M; Deng S; Li P; Xu B
Clin Epigenetics; 2017; 9():83. PubMed ID: 28814980
[TBL] [Abstract][Full Text] [Related]
8. Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma.
Shi Y; Dong M; Hong X; Zhang W; Feng J; Zhu J; Yu L; Ke X; Huang H; Shen Z; Fan Y; Li W; Zhao X; Qi J; Huang H; Zhou D; Ning Z; Lu X
Ann Oncol; 2015 Aug; 26(8):1766-71. PubMed ID: 26105599
[TBL] [Abstract][Full Text] [Related]
9. Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China.
Shi Y; Jia B; Xu W; Li W; Liu T; Liu P; Zhao W; Zhang H; Sun X; Yang H; Zhang X; Jin J; Jin Z; Li Z; Qiu L; Dong M; Huang X; Luo Y; Wang X; Wang X; Wu J; Xu J; Yi P; Zhou J; He H; Liu L; Shen J; Tang X; Wang J; Yang J; Zeng Q; Zhang Z; Cai Z; Chen X; Ding K; Hou M; Huang H; Li X; Liang R; Liu Q; Song Y; Su H; Gao Y; Liu L; Luo J; Su L; Sun Z; Tan H; Wang H; Wang J; Wang S; Zhang H; Zhang X; Zhou D; Bai O; Wu G; Zhang L; Zhang Y
J Hematol Oncol; 2017 Mar; 10(1):69. PubMed ID: 28298231
[TBL] [Abstract][Full Text] [Related]
10. A novel AF9 breakpoint in MLL-AF9-positive acute monoblastic leukemia.
Alonso CN; Longo PL; Gallego MS; Medina A; Felice MS
Pediatr Blood Cancer; 2008 Apr; 50(4):869-71. PubMed ID: 18000862
[TBL] [Abstract][Full Text] [Related]
11. A novel RT-qPCR assay for quantification of the MLL-MLLT3 fusion transcript in acute myeloid leukaemia.
Abildgaard L; Ommen HB; Lausen B; Hasle H; Nyvold CG
Eur J Haematol; 2013 Nov; 91(5):394-8. PubMed ID: 23772754
[TBL] [Abstract][Full Text] [Related]
12. Impact of loss of BH3-only proteins on the development and treatment of MLL-fusion gene-driven AML in mice.
Bilardi RA; Anstee NS; Glaser SP; Robati M; Vandenberg CJ; Cory S
Cell Death Dis; 2016 Sep; 7(9):e2351. PubMed ID: 27584789
[TBL] [Abstract][Full Text] [Related]
13. Long-term remission of therapy-related acute myeloid leukemia with a new t(11;18)(q23;q21.2) translocation and KMT2A-ME2 (MLL-ME2) fusion gene.
Szotkowski T; Jarošová M; Zimmermannová O; Meyer C; Marschalek R; Zuna J; Hubáček J; Indrák K
Cancer Genet; 2015 Dec; 208(12):610-4. PubMed ID: 26556690
[TBL] [Abstract][Full Text] [Related]
14. Complete molecular remission in refractory acute myeloid leukemia with MLL/AF9 treated with gemtuzumab ozogamicin.
Asano H; Yamamoto G; Hosoi M; Takahashi T; Hangaishi A; Kurokawa M
Leuk Res; 2010 Jul; 34(7):e152-3. PubMed ID: 20061019
[No Abstract] [Full Text] [Related]
15. MLL-AF9 and MLL-AF4 oncofusion proteins bind a distinct enhancer repertoire and target the RUNX1 program in 11q23 acute myeloid leukemia.
Prange KHM; Mandoli A; Kuznetsova T; Wang SY; Sotoca AM; Marneth AE; van der Reijden BA; Stunnenberg HG; Martens JHA
Oncogene; 2017 Jun; 36(23):3346-3356. PubMed ID: 28114278
[TBL] [Abstract][Full Text] [Related]
16. Impact of MLL::AF9 Gene Rearrangement on Survival of Acute Myeloid Leukaemia Patients: An Insight into Pakistani Population.
Tariq M; Shahab S; Saeed JR; Hussain Z; Zaidi U; Farzana T; Ahmad S
J Coll Physicians Surg Pak; 2024 Apr; 34(4):424-428. PubMed ID: 38576284
[TBL] [Abstract][Full Text] [Related]
17. Treatment of relapsed acute myelogeneous leukaemia with MLL/AF 6 fusion after stem cell transplantation by intensive reinduction followed by adoptive immunotherapy.
Schuster FR; Führer M; Woessmann W; Reiter A; Harbott J; Viehmann S; Borkhardt A
Leukemia; 2005 Jul; 19(7):1273-4; author reply 1275-6. PubMed ID: 15902291
[No Abstract] [Full Text] [Related]
18. MLL-AF9 and FLT3 cooperation in acute myelogenous leukemia: development of a model for rapid therapeutic assessment.
Stubbs MC; Kim YM; Krivtsov AV; Wright RD; Feng Z; Agarwal J; Kung AL; Armstrong SA
Leukemia; 2008 Jan; 22(1):66-77. PubMed ID: 17851551
[TBL] [Abstract][Full Text] [Related]
19. Transformation from acute promyelocytic leukemia in pregnancy to acute myeloid leukemia with MLL-AF9 fusion gene: A case report and literature review.
Gao Y; Han N; Jiang Y; Lu Z
Medicine (Baltimore); 2023 Dec; 102(48):e36403. PubMed ID: 38050244
[TBL] [Abstract][Full Text] [Related]
20. C-terminal BRE inhibits cellular proliferation and increases sensitivity to chemotherapeutic drugs of MLL-AF9 acute myeloid leukemia cells.
Pun CC; Lee KK; Chui YL
Leuk Lymphoma; 2019 Dec; 60(12):3011-3019. PubMed ID: 31111759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]